Heavy! Hang Seng Launches Biotech Latest Index First Ingredient Sons Exposed

On March 23, 2020, Hang Seng Index Co., Ltdannounced the launch of the Hang Seng Shanghai-Shenzhen-Hong Kong-To-China Biotech 50 Indexit is worth noting that this is basically seen as the first time the Hang Seng Index has launched an index specifically targeting biotechnologyAccording to the hang index website, it currently has 20 indices covering three themes: Hong Kong listing, mainland listing and cross-market, including more well-known indices such as the Hang Seng Index and the Hang Seng China Enterprises Indexbut in the existing index, the first is still lack of specifically for biotechnology companies, the second existing index of pharmaceutical companies coverage is relatively small, Hong Kong's leading pharmaceutical companies China Biopharmaceutical sand and stone pharmaceutical group is more concerned about the two companies, are also included in the Hang Seng Index and Hang Seng China Enterprises Index, also included in the Hang Seng China EnterpriseIndex, but also limited to a few companiesand the latest Hang Seng Shanghai-Shenzhen-Hong Kong-To-China Biotech 50 Index, as the name suggests, is reflecting the overall performance of bio-tech companies listed in Hong Kong or Chinese mainland and eligible for connectivity trading, with a total market capitalization ranking of the top 50The Hang Seng Index said the biotech companies in the index were companies defined as "biotech", "drugs" or "health care devices" in the business subcategories of the Hang Seng Industry Classification SystemThe new cross-market index provides a tradable benchmark for product issuers interested in the fast-growing industry of biotechnologyThe index is calculated and released instantly every two seconds, and its specific stock selection category has two criteria: the Hang Seng Composite Index component shares that are eligible to be traded through the Hong Kong Stock Exchange;From the selection criteria, first of all, the average daily turnover of Hong Kong stocks in the last six months was at least HK$20 million, the average daily turnover of A-shares in the last six months was at least 20 million yuan, and the Hang Seng Industry Classification System belongs to any of the pharmaceutical, biotechnology, health care equipment sub-categories of business, companies are eligible for electionthe number ofconstituent companies is fixed at 50, and the first 50 companies that have met the candidate criteria are selected based on the average market value of the companies in the last 12 monthsOn March 23rd the Hang Seng Shanghai-Shenzhen-Hong Kong-To-China Biotech 50 Index also launched the 10 most heavily-stocked companies as of March 20, 2020can see that these ten companies across the innovative drugs, generic drugs, blood products, biologics, CRO, CDMO, medical devices, the Internet and other fields, are in recent years, rapid development, good results and market value performance in the forefront of the industry enterprises, they can represent to a certain extent the rapid development of the biotechnology industry01, Hengrui led, China Biopharmaceutical and other leading companies were included in theMarch 15, 2020, Endpoints News listed the latest version of the global pharmaceutical company TOP50 listSix listed companies in China made the list, namely Hengrui Pharmaceuticals (22nd), Howson Pharmaceuticals (29th), Pharma Bio (33rd), China Biopharmaceuticals (36th), Shipharma Group (41st) and Baiji Shenzhou (47th) It also represents the market value of Chinese pharmaceutical companies, with Hengrui Pharmaceuticals with a market capitalisation of $55.98 billion (396 billion yuan, at today's exchange rate) and Baiji Shenzhou at $12.19 billion (86.2 billion yuan) Hengrui Pharmaceuticals' market capitalisation has been ranked around 20 in global pharmaceutical companies, while revenue is only about 40, compared with overseas pharmaceutical companies valuation shigh Tianfeng Securities believes that there are several reasons for the outside world to give Hengrui a higher valuation: first of all Hengrui has the advantage of performance growth Revenue growth for 2017-2019 was 24.71%, 26.5% and 33.7%, respectively, followed by the fact that China's pharmaceutical leaders have not yet opened a large-scale internationalization due to different historical stages of development, and have more room for growth as they move into the global market third point is that Hengrui has captured the I-O immune wave, introduced such a landmark product as PD-1, and pD-1 has several billion-level varieties (PARP inhibitor s2.6 billion, CDK4/6 inhibitor 4 billion, PD-L1 inhibitor 3 billion, etc.), the width of the pipeline layout can be benchmarked against the international pharmaceutical giants In addition, because Hengrui and overseas mature pharmaceutical companies in the historical stage is different, overseas large pharmaceutical companies are generally in the mature stage, and even "eight-year-old stores." If 2018 is seen as the first year of domestic innovation, Hengrui is still in the long term With the approval of more innovative drugs, taking into account the experience of overseas major pharmaceutical companies in their experience in increasing valuations, the approval of intensive innovative drugs will be followed by a double increase in valuation and market value China Biopharma was one of the first companies to enter the multi-billion market value club in China's pharmaceutical industry China Biopharmaceuticals once outranked Hengrui in the 2019 Global Pharmaceutical Top 50 based on prescription drug sales, outperforming Hengrui in prescription drug sales thanks to the chinese biopharmaceutical "King of imitation" name Excellent research and development hard power and patent challenges, decision-making and other soft power so that it in high-barrier genericdrugs ahead of competitors, such as the recently approved high-difficult inhalation of bude-hybrid fluid first imitation drug, in 2019 originally researched in China sales of 5.625 billion yuan, breaking the respiratory inhalation market for the monopoly of importers In addition, there are dry powder inhalants and other respiratory agents, patent challenges tofatib, Oberitic acid and other heavy imitation, so that China's biopharmaceutical generic business has maintained stable growth Stone Pharmaceutical Group is also recognized by the industry as a typical combination from generic drugs to imitation, to innovative pharmaceutical companies transformation of the success story In the first three quarters of 2019, Stone Pharma Group's Embip sales reached 4 billion yuan, and the anti-tumor product line grew by more than 20% driven by the expansion of the sales team and the sinking expansion But the industry's expectation of Stone Pharma Group lies in its continuous improvement of the research and development innovation layout In December 2019, Stone Pharmaceutical Group's Malay acid l-roedite chlorite was approved by the FDA for the new 505(b) (2) new drug, which not only proved its research and development strength, but also meant a deepening international layout 02, biopharmaceutical rookie as a biopharmaceutical field around 2010, Baiji Shenzhou and pharmaceutical Ming kangde, pharmaceutical mine biology are not to be ignored by the classic combination of scientists and entrepreneurs, Baiji Shenzhou, born to become the best partner in the field of new drug research and development, in 2016, in the general stock market has to withdraw from the environment, Baiji Shenzhou has bucked the trend, become the domestic number of venture biotech companies listed in the United States, the capital market can be seen to its attention from the product, baiji Shenzhou layout is high-flying PD-1 and BTK inhibitors, marketing, Baiji Shenzhou high salary to dig Uppf's Wu Xiaobin, and as early as 2017 on the test water and the new base company to reach a global strategic cooperation, in advance "grinding" marketing team and the internationalization of the paving From these layouts, it is not difficult to see the determination and action of Baiji Shenzhou "standing on the shoulders of giants" It is worth noting, however, that for the industry, Baiji Shenzhou is still a rookie role, BMS acquisition of the new base has indirectly affected Baiji Shenzhou, its independent research and development of PD-1 and BTK inhibitors exactly how well performance, still need time to verify the Wuxi drug Mingkangde and Pharmaceutical Synclaeus under the Mingkangde Group, is a typical representative of the rapid rise of China's new drug research and development transformation wave With the global pharmaceutical CRO industry boom, the domestic pharmaceutical CRO industry is developing rapidly, according to Frost and Sullivan statistics, the global CRO market size will increase to 72.7 billion U.S dollars in 2017-2022, China's CMO/CDMO industry in 2018 market size of 37 billion yuan At the same time, China's CRO industry to maintain a high business climate Drug review reform speed up the review speed, consistency evaluation, medical insurance control fee to force drug companies to innovative drugs transformation, join ich and international standards, these factors jointly promote pharmaceutical enterprises to increase investment in research and development, while the primary market small innovative pharmaceutical enterprises financing is active, science and technology board, Hong Kong stocks to provide more possible sources of funding The gradual shift of the global CRO industry chain to China is also a big contributing factor and has a first-mover advantage, for talent, technology, capital of the strong integration of capacity to make the drug Mingkang de As a similar company in the leading enterprises In recent years, the drug Mingkangde in the small molecule drug discovery business on the basis of continuous expansion, growing into the world's rare integrated layout CXO, through the CRO-Venture model has also successfully broken the ceiling of the traditional CXO business Fosun Pharma also acts as the representative of traditional Chinese pharmaceutical companies, but the ability to use industrial integration and Hengrui, Shimedicine and so on took a completely different path Since 2008, it has been building its own innovative small molecular medicine and bio-molecular drug platform, has gone to the United States to find talent and technology, hatched a number of bio-innovation enterprises such as Reinvention and Fuhong Hanxuan Today, Fuhong Hanxuan is listed on the Hong Kong Stock Exchange, and hanlikang, the first biosimilar drug, has been on the market for a year 03, deep-cultivated high-barrier track
Watson and Changchun high-tech features are selected and rooted in the Blue Sea track, to a certain extent, representing the domestic enterprises in this field synonymous Watson started from the traditional vaccine, adhering to the innovation-driven development of genes, focusing on the "vaccine s/ biological products and blood products" field, to innovative vaccines, monoclonal antibodies development At present, Watson Bio's most-watched heavyweight 13-price pneumonia vaccine is already in the end of approval The 13-price polysaccharide vaccine is a well-deserved "king of vaccine sales", with global sales of $5.8 billion in 2018, and Watson's capacity advantage and sales capability have been recognized and Watson Bio's international layout is also leading the industry, as early as 15 years ago, its controlling subsidiary signed with the Gates Foundation "low-cost HPV vaccine development and world health organization pre-certification" agreement, the Gates Foundation project fund support, 13-price vaccine-related cooperation is also under negotiation In June 2019, Changchun Gaoxin acquired a 29.5 percent stake in Jinsai Pharmaceuticals for 5,637 million yuan Combined with the 70 per cent stake already held by Kinsey Pharmaceuticals, Changchun Gaoxin will hold a 99.5 per cent stake in Kinsey Pharmaceuticals upon completion of the transaction Changchun Gaoxin never stopped the pursuit of the remaining shares of Jinsai Pharmaceuticals, which shows the "gold content" of Jinsai Pharmaceuticals itself It is the pioneer and leader of recombinant human growth hormone in China, with Asia's largest recombinant human growth hormone production line, but also the only international long-acting, water, powder three series of recombinant human growth hormone production base the number of children with dwarfism in China exceeds 5 million, and the market size and penetration rate are expanding as parents pay more attention to the physical development of adolescents And growth hormone is less affected by health insurance, Kinsey Pharmaceuticals in products, technology, scale, price, channels and other aspects of the accumulated advantages, as well as as the growth hormone industry the most complete dosage forms, the largest market share of the leading enterprises, making it a well-deserved "profit cow." in addition to Jinsai Pharmaceuticals, Changchun High-tech's Changchun Baike also has a number of heavy products worth looking forward to In February 2020, for example, Changchun Bacque launched a large-scale Phase III clinical trial of more than 25,000 people with herpes reduction live vaccine, a generic vaccine from Zostavax in Mersadon, which sold $668 million worldwide in 2017, while GSK's shingrix shingyr vaccine sold for more than $2 billion in its second year on the market 04, the two sub-industry representatives Murray Medical and Ali Health, respectively, on behalf of domestic medical device enterprises and Internet health care enterprises in China, the medical device industry belongs to the national key support of the strategic emerging industries China's medical device industry has grown rapidly, with a compound annual growth rate of about 23.89 percent from 2006 to 2016 At the same time, the policy dividend sons and more, the state implements the policy of graded diagnosis and treatment, and the grass-roots market demand is released rapidly To speed up the import substitution, the state supports domestic medical equipment, and encourages technological innovation of domestic equipment Murray Medical is the leader of domestic medical device companies, has maintained an independent research and development system, its global has eight research centers, has been higher than the same industry other companies research and development investment, research and development cost rate in the international leading level Coupled with the extension of mergers and acquisitions, Murray Healthcare accelerates the upgrade of its products to the high-end sector Covering the global sales network and professional after-sales service system, internationalization strategy has made Murray Medical a giant Murray Healthcare's market value exceeded 300 billion yuan in March 2020 Murray Medical has three main businesses, its one life information and support: the core product monitor advantages significantly, ventilators, infusion pumps, lamp tower, AED and other sub-products grow rapidly; Ali "big health ecology" carrier Ali health, from the initial electronic drug regulatory code gradually developed into a traceability platform, pharmaceutical e-commerce, consumer medicine, Internet medicine, smart medical five business sectors, involving patients, hospitals, doctors, medicine, insurance multi-party role The core source of profit for Ali Health is the proprietary pharmaceutical e-commerce business, which covers Ali Health Pharmacy, Ali Health Overseas flagship store and Ali Health flagship store And CICC has previously analyzed that a series of B-end, C-end enabling business not only for Ali Health cast moats, but also back-feeding the company's core business to achieve greater stickiness and higher market share Internet medical enterprises after several years of explosive development, the relevant enterprises have been groping out the formation of business, but more imagination is still being explored, which is the reason for Ali Health to become a representative of the Internet health care industry original title: Heavy! Hang Seng launched the latest biotechnology index, the first batch of component companies exposed, Hengrui, Stone Medicine and so on all shortlisted, who will join?